AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
A woman who is at least the fourth generation of her family to suffer a "cruel" brain disorder, which leaves people trapped ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
Hosted on MSN7d
New OHSU study examines potential link between PTSD, sleep issues and Parkinson's diseaseResearchers at Oregon Health & Science University (OHSU) are leading a study looking at a possible link between thrashing ...
HealthDay on MSN4d
FDA Approves Wearable Infusion Device for Advanced Parkinson DiseaseThe U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback